$144.60−7.88 (−5.17%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Palvella Therapeutics (PVLA) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue fell 17.6% in FY22, net margin −128.5%. Worth your attention in FY25: Returns vs FCF (n/m). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼139.3%
−41.7
FY21→FY25CAGR —
Free cash flow ($M)▼130.7%
−25.0
FY21→FY25CAGR —
Diluted EPS▲52.6%
−3.71
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Stock comp vs FCF
−25.6%
of free cash flow goes to stock comp (was 0.0% in FY21). Owner-earnings math treats it as a real cost.
Share count
+0.0%
11.3mn → 11.3mn diluted shares since FY25. Broadly flat, so EPS moves with net income rather than with the share count.
Returns vs FCF
n/m
$0.0M returned vs $−25.0M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level Gross Operating Net
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|
| Revenue & profitability | |||||||
Revenue | 0.0 | 0.0 | 0.0 | 25.9 | 31.4 | — | — |
Cost of revenue | 0.0 | 0.0 | 0.0 | 2.8 | 2.4 | — | — |
Gross profit | — | — | — | 23.1 | 29.1 | — | — |
Research & development | 22.8 | 8.2 | 8.8 | 50.2 | 64.2 | ▲180.2% | −22.8% |
Selling, general & admin | 15.8 | 5.9 | 3.1 | 16.4 | 16.7 | ▲165.2% | −1.4% |
Total operating expenses | 38.6 | 14.1 | 11.9 | 66.6 | 80.9 | ▲173.9% | −16.9% |
Operating incomefeeds ROC rank | −38.6 | −14.1 | −11.9 | −43.5 | −51.8 | ▼173.9% | — |
Other income, net | −3.1 | −3.3 | 30.6 | 10.2 | 6.1 | — | — |
Pretax income | −41.7 | −17.4 | 18.7 | −33.3 | −45.7 | ▼139.3% | — |
Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −41.7 | −17.4 | 18.7 | −33.3 | −45.7 | ▼139.3% | — |
| Per share | |||||||
Diluted EPSbuyback-sensitive | −3.71 | −7.83 | 14.74 | −29.61 | −56.69 | ▲52.6% | — |
Diluted shares (mn) | 11.25 | 2.23 | 1.27 | 0.93 | 0.81 | ▲405.4% | +93.2% |
| Margins | |||||||
Gross margin2nd pct in Healthcare | — | — | — | 89.3% | 92.5% | — | — |
Operating margin | — | — | — | −167.8% | −165.0% | — | — |
Net margin22nd pct in Healthcare | — | — | — | −128.5% | −145.6% | — | — |
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-31 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

